Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CLAUDIA MILY ESPINOSA

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1093840522
CMS profile
564928
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$18,359.74

38 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $18,265.08 37
ABBVIE INC. $94.66 1

Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CLAUDIA MILY ESPINOSA

NPI 1093840522 · CMS profile ID 564928

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093840522?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CLAUDIA MILY ESPINOSA, NPI 1093840522, CMS profile ID 564928. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093840522?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CLAUDIA MILY ESPINOSA, NPI 1093840522, CMS profile ID 564928. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093840522?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CLAUDIA MILY ESPINOSA, NPI 1093840522, CMS profile ID 564928, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1093840522?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

38 matching records · $18,359.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 38 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–38 of 38.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $1,348.0011/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356593 CMS
SANOFI PASTEUR INC. $50.0011/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356573 CMS
SANOFI PASTEUR INC. $135.7711/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356577 CMS
SANOFI PASTEUR INC. $73.0011/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356581 CMS
SANOFI PASTEUR INC. $40.0011/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356585 CMS
SANOFI PASTEUR INC. $20.3011/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356589 CMS
SANOFI PASTEUR INC. $8,080.0011/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356557 CMS
SANOFI PASTEUR INC. $393.0011/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356561 CMS
SANOFI PASTEUR INC. $128.4011/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356565 CMS
SANOFI PASTEUR INC. $263.0611/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356569 CMS
ABBVIE INC. $94.6607/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890929289 CMS
SANOFI PASTEUR INC. $54.0004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356441 CMS
SANOFI PASTEUR INC. $50.0004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356445 CMS
SANOFI PASTEUR INC. $70.0004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356449 CMS
SANOFI PASTEUR INC. $5,055.0004/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356453 CMS
SANOFI PASTEUR INC. $18.6004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356455 CMS
SANOFI PASTEUR INC. $15.4204/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356459 CMS
SANOFI PASTEUR INC. $40.0004/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356463 CMS
SANOFI PASTEUR INC. $42.0504/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356467 CMS
SANOFI PASTEUR INC. $345.8404/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356429 CMS
SANOFI PASTEUR INC. $188.0004/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356433 CMS
SANOFI PASTEUR INC. $129.0004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356437 CMS
SANOFI PASTEUR INC. $120.9601/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356499 CMS
SANOFI PASTEUR INC. $33.2201/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356507 CMS
SANOFI PASTEUR INC. $60.0001/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356511 CMS
SANOFI PASTEUR INC. $100.0001/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356547 CMS
SANOFI PASTEUR INC. $79.9701/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356483 CMS
SANOFI PASTEUR INC. $75.5001/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356487 CMS
SANOFI PASTEUR INC. $433.2801/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356495 CMS
SANOFI PASTEUR INC. $62.8301/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356515 CMS
SANOFI PASTEUR INC. $62.2201/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356519 CMS
SANOFI PASTEUR INC. $79.9701/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356523 CMS
SANOFI PASTEUR INC. $75.5001/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356527 CMS
SANOFI PASTEUR INC. $62.8301/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356551 CMS
SANOFI PASTEUR INC. $62.2201/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356553 CMS
SANOFI PASTEUR INC. $117.9601/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356479 CMS
SANOFI PASTEUR INC. $281.2501/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356491 CMS
SANOFI PASTEUR INC. $17.9301/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937356503 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,622.03 2
PY2020 $9,682.00 6
PY2021 $2,236.13 3
PY2022 $18,359.74 38
PY2023 $15,390.67 13
PY2024 $4,135.77 13
PY2025 $18,851.48 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $113,811.25 17
PY2024 Principal investigator $195,398.86 23
PY2023 Principal investigator $109,978.41 10
PY2022 Principal investigator $179,669.92 9
PY2021 Principal investigator $9,660.54 2
PY2020 Principal investigator $15,832.98 4
PY2019 Principal investigator $84,083.43 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,805.99 12/31/2023 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Phase 2 Open-label Uncontrolled Single-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Japanese Children - 24 Months of Age No dispute reported 06/30/2026 991130169
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,951.01 12/31/2023 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Phase 2 Open-label Uncontrolled Single-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Japanese Children - 24 Months of Age No dispute reported 06/30/2026 991130577
Principal investigator 1 Merck Sharp & Dohme LLC $8,849.54 12/31/2023 Non-covered Recipient Entity
University of South Florida-Department of Pediatrics
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease No dispute reported 06/30/2026 1042492359
Principal investigator 1 Merck Sharp & Dohme LLC $59.90 12/31/2023 Non-covered Recipient Entity
University of South Florida-Department of Pediatrics
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease No dispute reported 06/30/2026 1042492361
Principal investigator 1 Melinta Therapeutics, LLC $12,000.00 11/21/2023 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infection No dispute reported 06/30/2026 1056121099
Principal investigator 1 Merck Sharp & Dohme LLC $41,957.78 11/20/2023 Non-covered Recipient Entity
University of South Florida-Department of Pediatrics
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease No dispute reported 06/30/2026 1042492357
Principal investigator 1 Melinta Therapeutics, LLC $2,500.00 11/16/2023 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infection No dispute reported 06/30/2026 1056121095
Principal investigator 1 Janssen Research & Development, LLC $4,250.00 07/10/2023 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOA RD OF TRUSTEES
A Phase 3 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children =28 Days to =5 Years of Age and Subsequently in Neonates <28 Days of Age Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus RSV No dispute reported 06/30/2026 986152315
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,795.43 04/12/2023 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Phase 2 Open-label Uncontrolled Single-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Japanese Children - 24 Months of Age No dispute reported 06/30/2026 991124735
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,808.76 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Phase 2 Open-label Uncontrolled Single-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Japanese Children - 24 Months of Age No dispute reported 06/30/2026 991140679